Printer Friendly

Hypertension Management in Brazil: Usual Practice in Primary Care--A Meta-Analysis.

1. Introduction

Assessment of costs and health outcomes can generate estimates to compare and choose among screening, diagnostic, or therapeutic strategies, which should be incorporated into the healthcare system. The endpoint is to achieve maximum health gains with the available resources, respecting the expectations of the population covered by the healthcare system and considering the limited resources [1]. Health economic evaluations (HEES) are useful tools for managers and policy makers to choose the best allocation of available resources, or even about the assimilation of a new health technology. HEES are particularly useful to decide on incorporation of new strategies for prevention or control of noncommunicable diseases. In Brazil, the public health system, Sistema Unico de Saude (SUS), is based on universal free access to healthcare to the whole population, with decentralization provided at all levels, from prevention to high complexity level, shared by federal, state, and municipal government [2]. Blood pressure lowering medication are available at the SUS, freely distributed, and a list of drugs include thiazide diuretic, beta-blocker, ACE inhibitor, and an angiotensin receptor blocker (ARB). Health plan physicians are an alternative placed between the public and private systems, ranging from partial to full coverage, and usually with no refund for costs with blood pressure lowering agents. HEE is necessary to decide whether new drugs will be made available by the SUS.

It is estimated that hypertension (HT) affects 28.7% (95% CI: 26.2-31.4%) of the Brazilian adult population, with decreasing temporal trend in the rate of hypertension control [9]. In a meta-analysis of population-based studies, the control rate was 25% [9]. HT is responsible for significant global morbidity and mortality [10]. However, there is no systematic analysis of economic costs for diagnosis, risk stratification, and treatment of HT in Brazil [11].

A suitable HEE should include the comparison between the strategy of the Brazilian Guidelines of Hypertension [12] and the usual practice (status-quo), aiming at the primary prevention of CVD in patients of primary care. The statusquo can serve as a baseline for comparisons whenever a new health strategy is being considered for implementation [13]. Hence, our study aimed to describe the usual practice, in the context of primary care of the SUS in Brazil, regarding the diagnosis, risk stratification, and pharmacological treatment of HT.

2. Methods

2.1. Design and Data Sources. Studies conducted at population-based or outpatient, cross-sectional, or cohort studies, carried out since 2000, were searched in the databases of PubMed, EMBASE, and population-based databases of the Brazilian Virtual Health Library (VHL; http://brasil.bvs.br/ en/). The following search strategies were used: VHL using Descriptors in Health Sciences: "Hipertensao" AND "Atenfao Primaria a Saude" AND "Brasil"; on EMBASE using entrees: "brazil"/exp AND "hypertension"/exp AND "primary health care"/exp; and on PubMed using MeSH Terms: (("Hypertension"[Mesh]) AND "Primary Health Care"[Mesh]) AND "Brazil"[Mesh]. We also evaluated articles, which were included in a meta-analysis of the prevalence of hypertension [9], conducted by the authors. Articles that met the eligibility criteria were included: population-based cross-sectional or cohort studies performed in participants with 18 years or more, between 1980 and 2010. We also incorporated in meta-analysis four sets of data available to us, regardless of the systematic review searches [14-16].

2.2. Eligibility Criteria for the Review and Screening Process. Studies conducted in Brazil including patients with HT treated in any primary care facility affiliated to the SUS or population-based studies, which reported data in adults with HT were considered eligible for data extraction. Hospitalized patients were outside of the scope of this analysis and were excluded. The search results were handled in a double-screening process: their titles and abstracts were scrutinized and those eligible had their full-texts examined. Duplicated results were excluded. Studies conducted in pregnant women were excluded.

2.3. Target Population and Variables of Interest. The target population consisted of Brazilian adults ([greater than or equal to]18 years) who either had blood pressure (BP) [greater than or equal to] 140/90 mmHg or were on treatment with BP lowering agents (BPLM), enrolled from the general population or among those who were undertaking treatment in primary care settings. In order to collect information on management of patients and ensure comparability with the Brazilian Guidelines of Arterial Hypertension [12] and among guidelines [17], the following variables have been extracted: frequency of medical consultations and type of health insurance (e.g., SUS, private health plan) used most of the time, number and frequency of diagnostic tests suggested by this guideline (e.g., ECG, fasting glucose, and chest X-ray), antihypertensive classes, clinical characteristics, such as systolic BP (SBP), total and high-density lipoprotein cholesterol (HDL), and prevalence of other relevant comorbidities (diabetes mellitus (DM) and smoking) [18]. The rates of smoking and prevalence of DM among hypertensive individuals enrolled in the HIPERDIA (Brazilian Registration and Monitoring of Hypertensive and Diabetic Patients Program), from May 2002 to April 2012, were also evaluated [5].

2.4. Data Analysis. Continuous variables with normal distribution were presented as means and standard deviations (SD). Binary data were presented as proportions using point estimates and 95% confidence interval (95% CI). Meta-analyses were performed with the pooling of means or proportions: when the same variable of interest was measured using the same method across studies (e.g., self-reported diabetes versus fasting plasma glucose) and the same, or interchangeable, metric (e.g., one laboratory test per month equals 12 tests per year). Random effects model was mostly used; however, fixed effect model was employed when non-significant heterogeneity (p value [greater than or equal to] 0.05) was observed, as measured by Cochran's Q. The [I.sup.2] statistic was employed as a continuous measure of heterogeneity. Statistical analysis was performed in the Statistical Package for the Social Science (SPSS; version 17.0, IL, USA) and meta-analysis using Comprehensive Meta-Analysis (software version 2.0; Biostat, Englewood, NJ). Since this study is entirely descriptive, we did not formulate nor test any hypothesis.

3. Results

Figure 1 depicts the flow of search results in this review. The VHL search retrieved 31 results, PubMed 18 results, and EMBASE another 31 results. EMBASE and VHL retrieved identical results, which encompassed all the 18 articles found in PubMed. After the first screening and removal of overlapping result across databases, 19 articles were deemed eligible. Four studies reported data on at least one of the studied variables and were included in the meta-analysis. There were three available datasets: (i) two datasets from population-based cross-sectional studies conducted in large representative samples of two cities from Southern Brazil, Porto Alegre (capital of the state; SOFT study; n = 1858) [6, 7]; (ii) a third dataset was originated from a nationwide cross-sectional study conducted among 1148 industry workers (SESI study previously carried out by one of the authors) [3, 4]; (iii) a nationwide registry of hypertensive and diabetic patients treated in primary care of SUS (with of 7.3 million individuals on treatment for hypertension) collected from the HIPERDIA [5]. Another four studies included in a previous systematic review were considered eligible and, hence, were added to this meta-analysis along with the three aforementioned datasets, rendering a total of 11 studies [8,19-21].

Table 1 shows characteristics of the studies and HIPERDIA registry that provided data on clinical characteristics of individuals with HT according to sex. Studies that have data on mean systolic blood pressure and blood pressure control are presented in Table 1 as well. In the SESI study, men and women had similar SBP, but women had higher rate of hypertension control than men. In the population-based studies men and women had similar mean systolic blood pressure and rates of hypertension control. Higher prevalence of DM was observed among patients registered in HIPERDIA, especially in comparison to the participants of the SESI study. Smoking prevalence rates were more evenly distributed across the SESI study, HIPERDIA registry, and population-based studies, with higher prevalence of current smokers in men in comparison to women.

Table 2 presents information from seven studies that provided data on pharmacotherapy, diagnostic tests, and medical appointments. Less than half of the hypertensive subjects were using a single BPLM, and the most common class of BPLM was thiazide diuretics, followed by angiotensin-converting enzyme (ACE) inhibitors. Thiazide diuretics combined with ACE inhibitors were the most frequent 2-drug combination in use (14.9%), followed by thiazides and beta-blockers (9.4%).

Data on diagnostic tests came from one study, and estimates on most used type of medical services came from another study. Approximately a third of individuals with known HT had fasting plasma glucose, serum triglycerides, total cholesterol, and creatinine level measured in the previous 12 months. On average, an adult with HT had 2.6 medical appointments per year, and more than half of subjects who sought medical appointments used mostly those provided by the SUS. Figures 2, 3, and 4 are forest plots illustrating contents from Table 2. Figure 2 shows considerable heterogeneity among studies, mostly due to the study of Lima et al. [19], carried out in Rio de Janeiro.

4. Discussion

This systematic review examined all available databases that provide information on the management of HT among the Brazilian adult population. Some of them described the compliance with treatment guidelines of the State Health Department or provided an opinion on this matter [22, 23]. One article assessed physicians' compliance with HT treatment according to a Municipal Health Department guideline and detected noncompliance rates of 56.8%, 63.8%, and 54.0% regarding HT staging, cardiovascular risk classification, and choice of treatment, respectively [20].

Official data estimate that about 75% of the country's population depends exclusively on SUS for health care [24], but it has not been confirmed by the information from a population-based study carried out in the city of Pelotas [7]. The divergence may be explained by at least two biases from both sources of information: (i) the use of SUS services probably does not reach the 75% rate for all health conditions; (ii) recall bias of the medical appointments made in the previous month by participants of the population-based study. Nonetheless, the systematic review data derives from a single city; therefore it is hardly representative of the entire country.

Medical treatment by use of blood pressure lowering agents, conversely, was more often reported, so HT treatment data might be more representative of nationwide clinical practice within the SUS. Blood pressure control rates among individuals with HT could not be summarized through the results of all included studies, but it was reported for three population-based studies. The rates of controlled hypertension were higher than that reported in a previously systematic review, which identified a pooled control estimate of 24.1% (10.1-47.3%) [9]. The use of thiazide-type diuretics (as single or combined-drug therapy) was widespread in our analysis. This is in concordance with the best available evidence of effectiveness and current guidelines that advocate for the use of these drugs as first line treatment [12]. However, considering that there are few absolute contraindications for the use of diuretics, one may argue that the 41% usage rate should have been higher. On the other side, thiazide diuretics are more often used in Brazil than in Denmark, Finland, Germany, Norway, Sweden, Netherlands [25], Portugal [26], Spain [27], Mexico [28], and the United States [29]. Among other antihypertensive drugs, the use of beta-blockers was similar to that reported in other countries, but the prevalence of calcium channel blockers (CCB), ACE inhibitors, and ARBs use was much lower. CCB and ARB were rarely used to treat HT, since these drugs were not available in the SUS by the time that most of the studies were conducted. An ARB agent, by the opposite, was recently incorporated in the SUS.

Although there are several population-based studies that evaluated the prevalence of HT all over the country, only four studies provided information on how participants with hypertension were treated. The vast majority of these field studies restricted their assessment to measuring the prevalence of HT and other diseases among the general population, reporting little or no information with regard to individuals with HT (mean age of participants with HT, blood pressure control rates, etc.). Five studies reported the prevalence of hypertensive patients using one BPLM. The summary estimate of prevalence was reduced due to the weight of a study performed at a primary care center in Rio de Janeiro [19]. This study introduced heterogeneity due to the variability in the number of follow-up visits, ranging from 1 to 27, and to participants who did not use any medication (7.8%) and used two or more BPLMs (73.8%) and 18.4% who used only one drug to decrease BP. This study had a major contribution to the overall results.

Another limitation of the present study is the overall paucity of publications. This scarcity contrasts with a huge amount of data on patient management generated every day inside the SUS [2], with more than 40.4 million medical appointments recorded in the HIPERDIA registry from August 2011 to July 2012 [5].

Finally, our data did not cover the years since the new public program, Farmacia popular (popular pharmacy), for delivery of drugs and devices was launched, including the subsidized offering of losartan (90% of rebate). Twenty percent of the population is presently covered (http://www.brasil.gov.br/saude/2016/03/aqui-tem-farmacia-popular-atende- 38-milhoes-de-brasileiros-em-10-anos, accessed in December, 22, 2016). The impact of this program in the use of BP lowering drugs was not captured in the surveys available for this systematic review.

5. Conclusions

Despite these limitations, the estimates presented by this review are the best available evidence about the pattern of use of BP lowering drugs and rate of BP control in Brazil. Further studies should prospectively collect data to better describe the impact of new BP lowering agents. Thiazide diuretics and ACE inhibitors were the most frequently used as a single drug, and ACE inhibitors were the BP lowering medications more frequently prescribed, but the rate of hypertension control is insufficient.

Disclosure

The funding agencies had no participation in the planning or execution of the study or the analyses of the study data. An earlier version of this work was presented as an abstract at International Symposium on Cardiovascular Epidemiology.

https://doi.org/10.1155/2017/1274168

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

The authors contributed equally to the conceptual development of the study and subsequent draft of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES; MD/PhD Program), the National Council of Technological and Scientific Development (CNPq), and the Fundo de Incentivo a Pesquisa (FIPE) of the Hospital de Clinicas de Porto Alegre, RS, Brazil.

References

[1] M. Velasco-Garrido and R. Busse, "Health technology assessment: an introduction to objectives, role of evidence, and structure in Europe," World Health Organization 2005, on behalf of the European Observatory on Health Systems and Policies, http://www.euro.who.int/Document/E87866.pdf.

[2] J. Paim, C. Travassos, C. Almeida, L. Bahia, and J. MacInko, "The Brazilian health system: history, advances, and challenges," The Lancet, vol. 377, no. 9779, pp. 1778-1797, 2011.

[3] Servico Social da Industria, "Departamento Nacional. Unidade de Saude e Seguranca do Trabalho. Estudo SESI: perfil epidemiologico de fatores de risco para doenjas nao-transmissiveis em trabalhadores da industria do Brasil. Brasilia: CNI/SESI," 2007

[4] D. B. Vinholes, I. M. F. Melo, C. A. MacHado, H. De Castro Chaves, F. D. Fuchs, and S. C. Fuchs, "The association between socioeconomic characteristics and consumption of food items among Brazilian industry workers," The Scientific World Journal, vol. 2012, Article ID 808245,14 pages, 2012.

[5] Departamento de Informatica do SUS, "Informajoes de Saude: Epidemiologicas e Morbidade," April 2012, http://www2.datasus.gov.br/DATASUS/index.php?area=0203&VObj=http://tab- net.datasus.gov.br/cgi/deftohtm.exe?hiperdia/cnv/hd.

[6] D. J. Trevisol, L. B. Moreira, F. D. Fuchs, and S. C. Fuchs, "Health-related quality of life is worse in individuals with hypertension under drug treatment: results of population-based study," Journal of Human Hypertension, vol. 26, no. 6, pp. 374380, 2012.

[7] J. S. Dias Da Costa, S. C. Fuchs, M. T. Anselmo Olinto et al., "Cost-effectiveness of hypertension treatment: a populationbased study," Sao Paulo Medical Journal, vol. 120, no. 4, pp. 100104, 2002.

[8] G. C. Moreira, J. P. Cipullo, J. F. Vilela Martin et al., "Evaluation ofthe awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study," Journal of Hypertension, vol. 27, no. 9, pp. 1900-1907, 2009.

[9] R. V. Picon, F. D. Fuchs, L. B. Moreira, G. Riegel, and S. C. Fuchs, "Trends in prevalence of hypertension in Brazil: a systematic review with meta-analysis," PLoS ONE, vol. 7, no. 10, Article ID e48255, 2012.

[10] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies," The Lancet, vol. 360, no. 9349, pp. 1903-1913, 2002.

[11] M. I. Schmidt, B. B. Duncan, G. A. E Silva et al., "Chronic non-communicable diseases in Brazil: burden and current challenges," The Lancet, vol. 377, no. 9781, pp. 1949-1961, 2011.

[12] M. V. B. Malachias, W. K. S. B. Souza, F. L. Plavnik et al., "7th Brazilian Guideline of Arterial Hypertension," Arquivos Brasileiros de Cardiologia, vol. 107, pp. 1-83, 2016.

[13] M. F. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, and G. W. Torrance, Eds., Methods for the economic evaluation of health care programmes, chapters 8 and 9, Oxford University Press, Oxford, UK, 4th edition, 2015.

[14] M. Egger, G. D. Smith, and D. G. Altman, Systematic Review in Health Care: Meta-Analysis in Context, BMJ Publishing Group, London, UK, 2nd edition, 2003.

[15] M. Pai, M. McCulloch, J. D. Gorman et al., "Systematic reviews and meta-analyses: an illustrated, step-by-step guide," National Medical Journal of India, vol. 17, no. 2, pp. 86-95, 2004.

[16] M. J. Sculpher, F. S. Pang, A. Manca et al., "Generalisability in economic evaluation studies in healthcare: a review and case studies," Health Technology Assessment, vol. 8, no. 49, pp. 1-192, 2004.

[17] A. V. Chobanian, G. L. Bakris, H. R. Black et al., "Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure," Hypertension, vol. 42, no. 6, pp. 1206-1252, 2003.

[18] R. B. DAgostino Sr., R. S. Vasan, M. J. Pencina et al., "General cardiovascular risk profile for use in primary care: the Framingham heart study," Circulation, vol. 117, no. 6, pp. 743-753, 2008.

[19] S. M. L. Lima, M. C. Portela, I. Koster et al., "Use of clinical guidelines and the results in primary healthcare for hypertension," Cadernos de Saude Publica, vol. 25, pp. 2001-2011, 2009.

[20] I. Maluf Jr., M. R. Zahdi, N. Unterstell, E. M. C. P. Maluf, A. B. D. Sousa, and F. D. Loures, "Evaluation of physicians' compliance with the hypertension protocol of the Municipal Health Department of the city of Curitiba," Arquivos Brasileiros de Cardiologia, vol. 94, no. 1, pp. 86-91, 2010.

[21] J. J. G. de Souza, Hipertensao arterial referida e uso de anti- hipertensivos em adultos na cidade de Sao Paulo, 2003: um estudo de base populacional [M.S. thesis], Universidade de Sao Paulo, Faculdade de Saude Publica, Sao Paulo, Brazil, 2006.

[22] J. M. B. D. S. Costa, M. R. F. da Silva, and E. F. de Carvalho, "The implementation analysis of the arterial hypertension care by the Family Health teams in Recife city (Pernambuco, Brazil)," Ciencia e Saude Coletiva, vol. 16, no. 2, pp. 623-633, 2011.

[23] V. M. V. Paniz, A. G. Fassa, L. A. Facchini et al., "Free access to hypertension and diabetes medicines among the elderly: a reality yet to be constructed," Cadernos de Saude Publica, vol. 26, no. 6, pp. 1163-1174, 2010.

[24] Brasil. Ministerio da Saude. Organizajao Pan-Americana da Saude, Avaliagao do plano de reorganizagao da atencao a hipertensao arterial e ao diabetes mellitus no Brasil, Ministerio da Saude, Brasilia, Brazil, 2004.

[25] P. Stolk, B. L. G. Van Wijk, H. G. M. Leufkens, and E. R. Heerdink, "Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice," Journal of Human Hypertension, vol. 20, no. 12, pp. 917-922, 2006.

[26] C. Furtado and M. Pinto, "Antihypertensive drug utilization in Continental Portugal (1999-2004)," Revista Portuguesa de Cardiologia, vol. 25, article 27392, 2006.

[27] M. C. Caceres, P. Moyano, H. Farinas et al., "Trends in Antihypertensive Drug Use in Spanish Primary Health Care (19902012)," Advances in Pharmacoepidemiology & Drug Safety, vol. 4, no. 1, 2015.

[28] A. Alba-Leonel, A. Carvajal, I. Fierro et al., "Prescription patterns of antihypertensives in a community health centre in Mexico City: a drug utilization study," Fundamental and Clinical Pharmacology, vol. 30, no. 3, pp. 276-281, 2016.

[29] Q. Gu, V L. Burt, C. F. Dillon, and S. Yoon, "Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010," Circulation, vol. 126, no. 17, pp. 2105-2114, 2012.

Rafael V. Picon, (1) Juvenal S. Dias-da-Costa, (2) Flavio D. Fuchs, (3) Maria Teresa A. Olinto, (2) Niteesh K. Choudhry, (4) Sandra C. Fuchs (1,5)

(1) Postgraduate Studies Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul, R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, Brazil

(2) Postgraduate Program of Collective Health, Universidade do Vale do Rio dos Sinos, Sao Leopoldo, RS, Brazil

(3) Division of Cardiology, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

(4) Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard School of Medicine, Harvard University, Boston, MA, USA

(5) Postgraduate Studies Program in Epidemiology, School of Medicine, Universidade Federal do Rio Grande do Sul, R. Ramiro Barcelos 2600, 90035-003 Porto Alegre, RS, Brazil

Correspondence should be addressed to Sandra C. Fuchs; scfuchs@terra.com.br

Received 26 January 2017; Revised 7 May 2017; Accepted 16 May 2017; Published 2 July 2017

Academic Editor: Tomohiro Katsuya

Caption: Figure 1: Flow chart of records retrieved, screened, and included in the systematic review.
Table 1: Clinical characteristics of individuals with hypertension
from the SESI study, the HIPERDIA registry, and from meta-analyses of
four population-based studies.

Studies and clinical         Mean ([+ or -]SD)/prevalence (95% CI)
characteristics              Men                 Women

SESI study [3, 4]:           1034                114
participants (n)
Age (years)                  40.6 (11.8)         41.5 (9.2)
Systolic blood pressure      152.5 (15.9)        150.4 (21.7)
(mmHg)
Controlled blood pressure    31.8 (26.3-37.7)    56.9 (45.5-67.7)
Total cholesterol (mg/dL)    188.8 (40.0)        196.0 (39.2)
HDL cholesterol (mg/dL)      49.3 (20.9)         56.8 (12.7)
Current smokers              18.3 (15.9-20.7)    15.5 (8.9-22.1)
Diabetes mellitus (DM)       5.6 (4.2-7.0)       3.5 (0.1-6.9)
HIPERDIA registry [5]:       2.5 million         4.8 million
participants (n)
Current smokers              21.42 (20.4-22.5)   15.6 (14.7-16.5)
Diabetes mellitus            21.9 (19.8-24.0)    24.9 (22.9-27.0)
Current smokers with DM      6.3 (5.8-6.8)       5.6 (5.2-6.0)
Population-based studies:    5064                8126
participants (n)
Systolic blood pressure
(mm Hg)
  Trevisol et al. [6]        146.8 (20.7)        138.9 (22.6)
  Dias da Costa et al. [7]   144.5 (8.3)         146.1 (20.7)
Controlled blood pressure
  Trevisol et al. [6]        47.8 (39.7-56.1)    43.7 (38.5-49.2)
  Dias da Costa et al. [7]   65.7 (53.7-75.9)    67.5 (60.7-73.7)
Moreira et al. [8]           53.0 (46.9-58.4)    52.7 (45.6-58.9)
Current smokers              21.7 (17.2-27.0)    14.8 (10.1-21.0) *
                             ([double dagger])
Diabetes mellitus **         13.5 (12.5-14.4)    13.2 (8.3-20.7)
                             ([dagger])          ([dagger][dagger])

([double dagger]) Q p < 0.01; [I.sup.2] = 90.0%. * Data from 7867 women.
Q p < 0.01; [I.sup.2] = 94.1%. "''Fixed effect model analysis. Q p =
0.24; [I.sup.2] = 27.4%. ** Data from 4912 men and 7867 women;
[dagger]dagger] Q p < 0.01; [I.sup.2] = 87.3%.

Table 2: Frequency of blood pressure lowering medication use,
diagnostic tests, and medical appointments among hypertensive
subjects.

                              Prevalence         Heterogeneity
                              (95% CI)/mean
                              ([+ or -]SD)
                              Status quo         Q p value   [I.sup.2]

Blood pressure lowering
medication (%)
In use of one BPLM            42.7 (28.6-58.1)   <0.01       99.0
In use of two BPLM            33.0 (23.7-43.9)   <0.01       92.4
Type of BPLM
Thiazide diuretics
  Single-drug therapy or      41.1 (26.4-57.6)   <0.01       98.3
  combined with another
  drug
  Single-drug therapy         18.2 (7.4-38.4)    <0.01       96.6
  Combined with ACEI          14.9 (11.1-19.8)   <0.01       84.6
  Combined with BB            9.4 (5.7-15.2)     <0.01       86.5
  Combined with CCB [double   5.0 (2.4-7.6)      NA          NA
  dagger]
Angiotensin-converting
enzyme inhibitors (ACEI)
  Single-drug therapy or      41.1 (20.2-65.7)   <0.01       97.7
  combined with another
  drug
  Single-drug therapy         16.2 (11.6-22.1)   <0.01       85.0
  Combined with BB [dagger]   3.4 (2.5-4.7)      0.07        62.1
  Combined with CCB           4.0 (2.1-5.9)      NA          NA
  [double dagger]
Beta-blockers (BB)
  Single-drug therapy or      21.2 (17.3-25.8)   <0.01       84.3
  combined with other BPLM
  Single-drug therapy         10.0 (8.1-12.3)    0.17        46.2
  [dagger]
  Combined with CCB           2.3 (0.5-4.1)      NA          NA
  [double dagger]
Calcium channel blockers
(CCB)
  Single-drug therapy or      10.0 (7.5-13.3)    <0.01       72.4
  combined with other BPLM
  Single-drug therapy         3.9 (1.6-6.2)      NA          NA
  [double dagger]
Angiotensin receptor
blockers (ARB)
  Single-drug therapy or      2.3 (1.4-3.6)      0.06        71.2
  combined with other BPLM
  [dagger]
Diagnostic tests and
procedures (%) among
hypertensive subjects
Previous month testing
  Electrocardiography         6.3 (3.9-8.8)      NA          NA
  [double dagger]
  Any radiography             9.7 (6.8-12.7)     NA          NA
  [double dagger]
  Any urine test              8.4 (5.6-11.2)     NA          NA
  [double dagger]
  Any blood test              12.6 (9.3-16.0)    NA          NA
  [double dagger]
  Direct ophthalmoscopy**     35.0 (30.2-39.8)   NA          NA
  [double dagger]*
Previous 12-month testing
  Serum potassium [double     19.5 (13.9-25.2)   NA          NA
  dagger]
  Serum creatinine [double    31.0 (24.4-29.6)   NA          NA
  dagger]
  Total serum cholesterol     35.5 (28.7-42.3)   NA          NA
  [double dagger]
  Serum LDL or HDL            25.0 (18.3-31.2)   NA          NA
  cholesterol [double
  dagger]
  Serum triglycerides         34.0 (27.3-40.8)   NA          NA
  [double dagger]
  Fasting plasma glucose      36.5 (29.6-43.4)   NA          NA
  [double dagger]
  Urine analysis              25.0 (18.8-31.2)   NA          NA
  [double dagger]
Medical appointments (%)
among hypertensive subjects
  Annual mean of medical      2.62 (2.37)        0.5         0
  appointments
  Mostly using Brazilian      51.2 (46.1-56.2)   NA          NA
  Health Care System
  [double dagger]
  Mostly using private        20.9 (16.8-25.1)   NA          NA
  physicians [double
  dagger]
  Mostly using health plan    13.0 (9.6-16.4)    NA          NA
  physician [double dagger]
  Mostly using emergency      1.9 (0.5-3.2)      NA          NA
  services [double dagger]
  Others [double dagger]      13.0 (9.6-16.4)    NA          NA

[dagger] Fixed effect analysis. [double dagger] Based on one study. *
Since the diagnosis of hypertension; LDL: low-density lipoprotein;
HDL: high-density lipoprotein; Q p value and [I.sup.2]-:
nonapplicable; that is, only one study provided data; NA: not
applicable.

Figure 3: Meta-analysis of proportion of use of two blood pressure
lowering medication.

First author        Year   City          Sample   %      95% CI
                                         size

Dias da Costa [7]   2002   Pelotas       262      53.0   46.9-59.0
de Souza [21]       2003   Sao Paulo     392      46.7   41.8-51.6
Moreira [8]         2009   Sao Jose do   549      44.6   40.5-48.8
                           Rio Preto
Lima [19]           2009   Rio de        3133     18.4   17.1-19.8
                           Janeiro
Maluf [20]          2010   Curitiba      189      57.0   49.8-63.9
Summary                                  4525     42.7   28.6-58.1
                           Summary [T.sup.2] = 0.82, Q < 0.01,
                           [I.sup.2] = 99.0%

BPLM: blood pressure lowering medication; 95% CI: 95% confidence
interval.

Figure 2: Meta-analysis of proportion of use of one BPLM (in
chronological order according to the data collection year).

First author    Year   City             Sample   %      95% CI
                                        size

de Souza [21]   2003   Sao Paulo        392      22.4   18.5-26.8
Moreira [8]     2009   S. Jose do Rio   549      41.2   37.2-45.4
                       Preto
Lima [19]       2009   Rio de Janeiro   3133     37.2   35.5-38.9
Maluf [20]      2010   Curitiba         189      32.5   26.2-39.5
Summary                                 4263     33.0   23.7-43.9
                       Summary [T.sup.2] = 0.09, Q < 0.01,
                       [I.sup.2] = 92.4%

BPLM: blood pressure lowering medication; 95% CI: 95% confidence
interval.

Figure 4: Meta-analysis of proportion of use of thiazide-based
therapy.

Type of therapy   First author    Year   Sample          95% CI
                                         size %

Single-drug or
combined          Dias da Costa   2002   262      57.9   51.8-63.7
                  de Souza        2003   392      32.6   28.2-37.4
                  Moreira         2009   549      39.9   35.8-44.0
                  Maluf           2010   189      51.5   44.4-58.5
                  Santa Helena    2006   565      26.0   22.5-29.8
                  Hoepfner        2007   415      72.4   67.9-76.5
                  Trevisol        2012   426      44.4   39.7-49.1
                  Summary                2798     46.1   33.2-59.6
                                  Summary [[tau].sup.2] = 0.44,
                                  Q < 0.01,
                                  [I.sup.2] = 97.5%
Single-drug
                  Dias da Costa   2002   262      27.4   22.3-33.1
                  Moreira         2009   549      11.6   9.2-14.6
                  Summary                811      18.2   7.4-38.4
                                  Summary [[tau].sup.2] = 0.53,
                                  Q < 0.01,
                                  [I.sup.2] = 96.6%
Combined with
ACEI              Dias da Costa   2002   262      11.0   7.7-15.4
                  de Souza        2003   392      11.0   8.3-14.5
                  Moreira         2009   549      19.5   16.4-23.0
                  Santa Helena    2006   565      18.6   15.6-22.0
                  Summary                1768     14.9   11.07-19.7
                                  Summary [[tau].sup.2] = 0.10,
                                  Q < 0.01,
                                  [I.sup.2] = 84.6%
Combined with
BB                Dias da Costa   2002   262      15.0   11.2-19.9
                  de Souza        2003   392      6.0    4.0-8.8
                  Moreira         2009   549      8.7    6.7-11.4
                  Summary                1203     9.4    5.7-15.2
                                  Summary [[tau].sup.2] = 0.20,
                                  Q < 0.01,
                                  [I.sup.2] = 86.5%

ACEI: angiotensin-converting enzyme inhibitors; BB: beta-blockers; 95%
CI: 95% confidence interval.


Please Note: Illustration(s) are not available due to copyright restrictions.
COPYRIGHT 2017 COPYRIGHT 2010 SAGE-Hindawi Access to Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Picon, Rafael V.; Dias-da-Costa, Juvenal S.; Fuchs, Flavio D.; Olinto, Maria Teresa A.; Choudhry, Ni
Publication:International Journal of Hypertension
Date:Jan 1, 2017
Words:5121
Previous Article:Duration of electrically induced atrial fibrillation is augmented by high voltage of stimulus with higher blood pressure in hypertensive rats.
Next Article:Review of and Updates on Hypertension in Obstructive Sleep Apnea.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |